Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6230-6237

  Bolli, Niccolò ^a   Nicoletti, Ildo ^a   De Marco, M Felicetta ^a   Bigerna, Barbara ^a   Pucciarini, Alessandra ^a   Mannucci, Roberta ^a   Martelli, Maria Paola ^b   Liso, Arcangelo ^c   Mecucci, Cristina ^a   Fabbiano, Francesco ^d   Martelli, Massimo F ^a   Henderson, Beric R ^e   Falini, Brunangelo ^a,f  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^e WESTMEAD HOSPITAL   (Australia)

^f Institute of Hematology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; NUCLEOPHOSMIN; TRYPTOPHAN;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BIOASSAY; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; LEUKEMOGENESIS; MOUSE; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEOCYTOPLASMIC TRANSPORT; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MOTIF; WILD TYPE;

AMINO ACID MOTIFS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOPLASM; DNA MUTATIONAL ANALYSIS; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; MICROSCOPY, FLUORESCENCE; MUTATION; NIH 3T3 CELLS; NUCLEAR PROTEINS; PLASMIDS; PROTEIN STRUCTURE, TERTIARY;

EID: 34447134905     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0273     Document Type: Article

References (38)

1. Macara IG. Transport into and out of the nucleus. Microbiol Mol Biol Rev 2001;65:570-94.
2. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004;4:106-17.
3. Fornerod M, Boer J, van Baal S, et al. Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene 1995;10:1739-48.
4. Nakamura T. NUP98 fusion in human leukemia: dysregulation of the nuclear pore and homeodomain proteins. Int J Hematol 2005;82:21-7.
5. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66.
6. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989;56:379-90.
7. Cordell JL, Pulford KA, Bigerna B, et al. Detection of normal and chimeric nucleophosmin in human cells. Blood 1999;93:632-42.
8. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106:3733-9.
9. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740-6.
10. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005;106:3747-54.
11. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011-20.
12. Falini B, Bolli N, Shan J, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006;107:4514-23.
13. Nakagawa M, Kameoka Y, Suzuki R. Nucleophosmin in acute myelogenous leukemia [letter]. N Engl J Med 2005;352:1819-20.
14. Falini B, Martelli MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006;108:1999-2005.
15. Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood 2006;108:4146-55.
16. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biological and clinical features. Blood 2007;109:874-85.
17. Nishimura Y, Ohkubo T, Furuichi Y, Umekawa H. Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization. Biosci Biotechnol Biochem 2002;66:2239-42.
18. Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997;90:1051-60.
19. Meissner T, Krause E, Vinkemeier U. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms. FEBS Lett 2004;576:27-30.
20. Henderson BR, Eleftheriou A. A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. Exp Cell Res 2000;256:213-24.
21. Yu Y, Maggi LB, Jr., Brady SN, et al. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol 2006;26:3798-809.
22. Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 2005;7:823-30.
23. Kalland KH, Szilvay AM, Brokstad KA, Saetrevik W, Haukenes G. The human immunodeficiency virus type 1 Rev protein shuttles between the cytoplasm and nuclear compartments. Mol Cell Biol 1994;14:7436-44.
24. Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005;19:1760-7.
25. Andersen JS, Lam YW, Leung AK, et al. Nucleolar proteome dynamics. Nature 2005;433:77-83.
26. la Cour T, Gupta R, Rapacki K, Skriver K, Poulsen FM, Brunak S. NESbase version 1.0: a database of nuclear export signals. Nucleic Acids Res 2003;31:393-6.
27. Zhang MJ, Dayton AI. Tolerance of diverse amino acid substitutions at conserved positions in the nuclear export signal (NES) of HIV-1 Rev. Biochem Biophys Res Commun 1998;243:113-6.
28. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003;112:29-40.
29. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004;24:985-96.
30. Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem 2000;275:24451-7.
31. Engelsma D, Bernad R, Calafat J, Fornerod M. Supraphysiological nuclear export signals bind CRM1 independently of RanGTP and arrest at Nup358. EMBO J 2004;23:3643-52.
32. Henderson BR, Fagotto F. The ins and outs of APC and h-catenin nuclear transport. EMBO Rep 2002;3:834-9.
33. Mariano AR, Colombo E, Luzi L, et al. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal. Oncogene 2006;25:4376-80.
34. Albiero E, Madeo D, Bolli N, et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia. Epub 2007 Feb 15.
35. den Besten W, Kuo ML, Williams RT, Sherr CJ. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 2005;4:1593-8.
36. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006;6:493-505.
37. Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005;106:1419-22.
38. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106:2854-61.